GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Erica® (China)
glecirasib is an approved drug
Compound class:
Synthetic organic
Comment: Glecirasib is a KRASG12C inhibitor.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Glecirasib is proposed to treat advanced non-small cell lung cancer (NSCLC) harbouring KRASG12C oncogenic mutation. First approval was granted by China's NMPA in 2025, to treat KRASG12C advanced NSCLC [1]. |